Adjei AA, Sosman JA, Martell RE, et al. Efficacy in selected tumor types in a phase I study of the c-Met inhibitor ARQ 197 in combination with sorafenib. J Clinical Oncology 2011; 29(15_suppl): 3034.
An S, Yu J, Xu T, Hao P. Application of dictamnine in preparation of c-Met inhibitor for treating cancer. CN110755435, 2020.
Duan M, Liu J, Tian S, Deng W, Yan C, Zhao L. Preparation of the multi-substituted pyridone derivatives and medical applications. WO2020042618, 2020.
Duan M, Liu J, Tian S, Dai Q, Xiong Y. Polysubstituted pyridonederivative useful in treatment of cancer and its preparation. WO2019080723, 2019.
Xu X, Li G, Ding C- Z, et al. Pyridone compound as c-Met inhibitor. WO2018077227, 2018.
Xu X, Li G, Yao T, Wang K, Hu L, Ding CZ. Crystal form of c-Met inhibitor and salt form thereof and preparation method therefor. WO2019206268, 2019.
Chen G. Compounds as c-Met kinase inhibitors. WO2012034055, 2012.
Gong F, Huang T, Zang H, Zhang S, Zhao R, Liu F. Preparation of N-[4-[[7-[[1-(cyclopentylamino)cyclopropyl]methoxy]-6- methoxy-4-quinolinyl oxy]-3-fluorophenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide crystal as c-Met kinase inhibitor for treatment of cancer. WO2019166012, 2019.
Zhang Q, Yu S, Wang Z, et al. Dioxazoline compound, preparation method therefor, and uses thereof. WO2019154133, 2019.
Zhang Q, Zhang H, Yang L, et al. Dioxanoquinazoline, dioxanoquinazoline-type compound, preparation method and application. WO2018153293, 2018.
Zhao Z, Wang H, Wu C. [1,2,4] triazol [4,3-a] pyridine derivate preparation method therefor or medical application thereof. WO2014180182, 2014.
Li X, Zhang L, Sun Q, Lv A. Crystalline free base of C-MET inhibitor or crystalline acid salts, preparation methods and application. WO2016015653, 2016.
Yang B, Zhu Q, Pan B. Method for preparing c-Met tyrosine kinase inhibitor. CN106883250, 2017.
Yang B, Zhu Q, Pan B. Method for preparing c-Met tyrosine kinase inhibitor. WO2017101885, 2017.
Zhang Y, Chen Z, Wang Y, et al. Preparation of the azaindole derivative and their application as the c-Met inhibitor for the treatment of cancer. WO2020015744, 2020.
Hinklin RJ, Allen S, Barbour P, et al. Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases and their preparation. WO2020047184, 2020.
Zheng P, Zhu W, Tang Q, et al. Preparation of antitumor pyrrolopyrimidines. CN107383016, 2017.
Zhu W, Zheng P, Wang L, et al. Thienopyrimidine compound containing heteroaryl amide structure useful in treatment of cancer and its preparation. CN107253964, 2017.
Zhao G, Zhao Y, Hu Y. Preparation of the indole-based small molecule C-MET inhibitor applied to treatment of cancers. CN107311983, 2017.
Zhao G, Hou Y, Zhao Y. Method for preparing indole type c-Met inhibitor. CN107382968, 2017.
Tang Q, Zheng P, Zhu W, et al. 1-Aryl-4-oxy-1,4-dihydroquinoline structure of pyridine and heterocyclic compound, preparation method and its application. CN108948014, 2018.
Li X, Li D, Hong R. Preparation of c-Met inhibitor as anti-cancer drug. CN110218191, 2019.
Huang W, Qian H, Gu W. Preparation of the 2,4-disubstituted pyridine and their medicine application for the treatment of cancer. CN108069938, 2018.
Li Q, Hu L, Dong H, et al. 3-(4-Fluorophenyl pyrimidone)-5-carboxamide derivative useful in treatment of cancer and its preparation. CN106543145, 2017.
Li Y, Geng M, Cui H, Ai J, Zhang W, Peng X. Quinolinones compound, preparation method, and use thereof. CN106146464, 2016.
Unknown. c-Met/HDAC double-target inhibitor based on crizotinib structure and synthesis method for antitumor drug. CN110003181, 2019.
Unknown. c-Met/HDAC double-target inhibitor, its synthesis method and application in preparing antitumor drugs. CN110128411, 2019.
Unknown. Novel c-Met/HDAC dual-target inhibitor and its synthesis method for antitumor drug preparation. CN110016013, 2019.
Cai P, Wang B. Preparation of 2,4-disubstituted triazole compounds with ALK and c-Met inhibition activities. CN105348265, 2016.
Hao H, Huang X, Tam A, Kasibhatla S. Combination cancer therapy. WO2016016822, 2016.
Ren G, Yi D, Chen J. A crystal form of triazolopyrazine derivative and preparation method. CN105503906, 2016.
Ren G, Yi D, Chen J. B crystal form of savolitinib. CN105503905, 2016.
Yu J, Hao Y, Zhang J, et al. Salt of quinolone compound, polymorphs thereof, preparation method therefor, composition, and applications. WO2017114452, 2017.
Yu J, Guo L, Zhao F, et al. Quinoline-series compound, its preparation method, and pharmaceutical application. CN104109166, 2014.
Wu B, Shao S, Liu J. Compound containing the pharmaceutical composition and its application. CN108276418, 2018.
Frigault MM. Use of c-Met inhibitors to treat cancers harbouring met mutations. WO2018055029, 2018.
Shim SH, Lee J, Jung SY, et al. Combination therapy of c-Met-associated cancers using c-Met inhibitors and IGF-1 receptor inhibitors. US20160144027, 2016.
Aftab DT, Lamb P. Drug combinations to treat multiple myeloma. WO2016022697, 2016.